The firm also offered updates on its autoimmune disease, newborn screening, and other specialty diagnostics businesses from the sidelines of the conference.

The issue of developing pediatric reference intervals for common laboratory tests has been one of the organization's priorities.

Last week, readers were most interested in a story about a staffing shortage at labs that run liquid biopsy tests as demand for the tests skyrocket.

Executives disclosed new directions in neurodegenerative disease testing and low-volume sample collection for high-volume testing.

Genprex plans to potentially integrate TROP2 expression for patient selection in NSCLC clinical studies, while Roche will validate assays using its TROP2 antibody.

The ELISA-based CIZ1B Biomarker Blood Test for Lung Cancer is designed to detect the lung cancer-produced biomarker CIZ1B. It was developed by UK-based Cizzle Biotechnology, which licensed it in the ...

The company reported Q2 2026 revenue of $3.73 billion compared to $3.53 billion in the year-ago period, beating Wall Street's consensus estimate of $3.71 billion.

The Chicago-based company is developing a POC field-effect transistor (FET)-based analyzer that it plans initially to target to the fertility testing space.

HHS OIG issued five recommendations, including refunding the federal government $18.5 million, as well as additional refunds for other potential overpayments.

The Helsinki-based company said it will use the funds to support further development of its AI-based digital pathology platform.

Staffing is an issue for the clinical lab industry writ large, but rapid growth in demand and quickly changing technology has made liquid biopsies a particularly tricky area.

A panel discussion at the Association for Diagnostics & Laboratory Medicine this week tackled questions around coding, reimbursement, and regulation of AI-based tests.